[feed] Atom [feed] RSS 1.0 [feed] RSS 2.0

Kumar , J. and Kale , V. and Limaye , L. (2015) Umbilical cord blood-derived CD11c+ dendritic cells could serve as an alternative allogeneic source of dendritic cells for cancer immunotherapy. Stem Cell Research & Therapy, 25 (6). p. 184.

[img]
Preview
Text
52. Dr. Limaye L. (Stem cell Res. Ther.) paid open access.pdf

Download (1108Kb) | Preview

Abstract

Allogenic dendritic cells (DCs) generated from healthy donors, who are complete or partially HLA-matched, have been used for clinical trials. One of the sources for allogenic DCs is umbilical cord blood (UCB) cells. However, as far as cord blood cells are concerned, looking at their naïve nature, there is a concern as to whether the DCs generated from them will have enough potential to elicit a proper T cell response. For this, we compared CD11c+ UCB-DCs/ Cytotoxic T lymphocytes (CTLs) with the conventional source, i.e. peripheral blood (PBL) monocyte DCs/CTLs, using various parameters.

Item Type: Article
Subjects: Stem Cell Biology
Depositing User: Mr. Rameshwar Nema
Date Deposited: 04 Dec 2015 06:37
Last Modified: 19 Feb 2016 08:13
URI: http://nccs.sciencecentral.in/id/eprint/206

Actions (login required)

View Item View Item